[go: up one dir, main page]

ES2721930T3 - Composición inmunogénica - Google Patents

Composición inmunogénica Download PDF

Info

Publication number
ES2721930T3
ES2721930T3 ES13801540T ES13801540T ES2721930T3 ES 2721930 T3 ES2721930 T3 ES 2721930T3 ES 13801540 T ES13801540 T ES 13801540T ES 13801540 T ES13801540 T ES 13801540T ES 2721930 T3 ES2721930 T3 ES 2721930T3
Authority
ES
Spain
Prior art keywords
fragment
immunogenic composition
toxin
isolated
clostridium difficile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13801540T
Other languages
English (en)
Inventor
Dominique Boutriau
Sophie Marie Jeanne Valentine Germain
Hugues Wallemacq
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Application granted granted Critical
Publication of ES2721930T3 publication Critical patent/ES2721930T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composición inmunogénica que comprende: a) un polipéptido que comprende un fragmento aislado de toxina A de Clostridium difficile y un fragmento aislado de toxina B de Clostridium difficile; y b) un coadyuvante que comprende una fracción de saponina inmunológicamente activa presentada en forma de un liposoma; en la que el polipéptido comprende un fragmento del dominio de repetición de la toxina A y un fragmento del dominio de repetición de la toxina B.
ES13801540T 2012-12-05 2013-12-03 Composición inmunogénica Active ES2721930T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201221875 2012-12-05
PCT/EP2013/075405 WO2014086787A1 (en) 2012-12-05 2013-12-03 Immunogenic composition

Publications (1)

Publication Number Publication Date
ES2721930T3 true ES2721930T3 (es) 2019-08-06

Family

ID=49724573

Family Applications (2)

Application Number Title Priority Date Filing Date
ES13801540T Active ES2721930T3 (es) 2012-12-05 2013-12-03 Composición inmunogénica
ES19159001T Active ES2939307T3 (es) 2012-12-05 2013-12-03 Composición inmunogénica

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES19159001T Active ES2939307T3 (es) 2012-12-05 2013-12-03 Composición inmunogénica

Country Status (22)

Country Link
US (2) US9694064B2 (es)
EP (2) EP3513806B1 (es)
JP (2) JP6290918B2 (es)
CN (2) CN104884081A (es)
AR (1) AR093712A1 (es)
AU (1) AU2013354186A1 (es)
BR (1) BR112015012841B1 (es)
CA (1) CA2893435C (es)
CY (1) CY1121560T1 (es)
DK (2) DK3513806T5 (es)
ES (2) ES2721930T3 (es)
FI (1) FI3513806T3 (es)
HR (2) HRP20230359T1 (es)
HU (2) HUE061273T2 (es)
LT (2) LT3513806T (es)
PL (2) PL3513806T3 (es)
PT (2) PT2928489T (es)
SG (1) SG11201503861UA (es)
SI (2) SI2928489T1 (es)
TR (1) TR201905272T4 (es)
WO (1) WO2014086787A1 (es)
ZA (1) ZA201503927B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0612655B1 (pt) * 2005-06-27 2021-06-15 Pfizer Ireland Pharmaceuticals Composição imunogênica
ES2867375T3 (es) 2010-09-03 2021-10-20 Valneva Austria Gmbh Polipéptido aislado de las proteínas de la toxina A y la toxina B de C. difficile y sus usos
BR112013027229B1 (pt) 2011-04-22 2020-10-27 Wyeth Llc polipeptídeo imunogênico isolado e seu uso, composição imunogênica e seu uso, célula recombinante ou progênie da mesma, e método de produção de uma toxina de clostridium difficile mutante
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
PL3513806T3 (pl) * 2012-12-05 2023-05-15 Glaxosmithkline Biologicals Sa Imunogenna kompozycja
EP3636278A3 (en) * 2014-06-25 2020-07-15 GlaxoSmithKline Biologicals S.A. Clostridium difficile immunogenic composition
DK3174553T3 (en) * 2014-07-25 2018-07-23 Biosynth Srl GLYCOCOONJUGATE VACCINES INCLUDING BASIC UNITS OF A MOLECULE CONSTRUCTION THAT EXPRESSES MULTIPLE INTEGRATED EPITOPES FOR THE FORMULATION OF A WIDE-SPECTED VACCINE AGAINST INFECTIONS BASED ON BACTEROGEN
ES2870506T3 (es) 2015-02-19 2021-10-27 Immune Biosolutions Inc Antígeno y anticuerpo del epítopo de las toxinas a y/o b de clostridium difficile, y sus usos farmacéuticos
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2017165398A1 (en) 2016-03-21 2017-09-28 Children's Medical Center Corporation Compositions and methods for inhibiting wnt signaling
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2018170238A2 (en) * 2017-03-15 2018-09-20 Novavax, Inc. Methods and compositions for inducing immune responses against clostridium difficile
CN107397956A (zh) * 2017-08-08 2017-11-28 南开大学 一种铜绿假单胞菌外膜蛋白疫苗的制备方法及应用
CN112512556A (zh) 2018-01-16 2021-03-16 儿童医学中心公司 用于抑制wnt信号传导的组合物和方法
GB201804092D0 (en) * 2018-03-14 2018-04-25 Imperial Innovations Ltd Methods and compositions
US10933126B2 (en) 2018-05-03 2021-03-02 The Board Of Regents Of The University Of Oklahoma Clostridium difficile immunogenic compositions and methods of use
WO2020237090A1 (en) * 2019-05-21 2020-11-26 The Regents Of The University Of California Vaccine compositions for clostridium difficile
WO2021255690A2 (en) * 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
IL320955A (en) * 2022-12-13 2025-07-01 Pfizer Immunogenic compounds and methods for generating an immune response against CLOSTRIDIIOIDES (CLOSTRIDIUM) DIFCILE
CN120615016A (zh) 2023-02-02 2025-09-09 葛兰素史克生物有限公司 免疫原性组合物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
EP0362278A4 (en) 1987-06-05 1990-05-14 Us Health Autocrine motility factors in cancer diagnosis and management.
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ATE115862T1 (de) 1989-02-04 1995-01-15 Akzo Nobel Nv Tocole als impfstoffadjuvans.
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
DE69327599T2 (de) 1992-06-25 2000-08-10 Smithkline Beecham Biolog Adjuvantien enthaltende Impfstoffzusammensetzung
AU685443B2 (en) 1993-03-23 1998-01-22 Smithkline Beecham Biologicals (Sa) Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
PL320214A1 (en) 1994-10-24 1997-09-15 Ophidian Pharmaceuticals Vaccine and antitoxin for treating and preventing a disease caused by c.difficile
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP2305293A3 (en) 1997-10-20 2013-11-06 Sanofi Pasteur Biologics Co. Immunization against Clostridium difficile disease
AU781175B2 (en) 1999-04-09 2005-05-12 Intercell Usa, Inc. Recombinant toxin A/toxin B vaccine against Clostridium Difficile
US6733760B1 (en) * 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
WO2001073030A2 (en) 2000-03-28 2001-10-04 Diadexus, Inc. Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer
US20090028903A1 (en) * 2005-03-23 2009-01-29 Glaxosmithkline Biologicals, S.A. Novel use
GB0525321D0 (en) * 2005-12-13 2006-01-18 Glaxosmithkline Biolog Sa Novel compositions
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
DK2086582T3 (da) 2006-10-12 2013-02-04 Glaxosmithkline Biolog Sa Vaccine omfattende en olie-i-vand-emulsionsadjuvans
GB0711858D0 (en) * 2007-06-19 2007-07-25 Glaxosmithkline Biolog Sa Vaccine
AU2008299885C1 (en) 2007-09-14 2015-06-25 Sanofi Pasteur Biologics, Llc Pharmaceutical compositions containing clostridium difficile toxoids A and B
HUE026586T2 (hu) * 2008-04-16 2016-06-28 Glaxosmithkline Biologicals Sa Vakcina
US20120020996A1 (en) * 2008-08-06 2012-01-26 Jonathan Lewis Telfer Vaccines against clostridium difficile and methods of use
ES2867375T3 (es) * 2010-09-03 2021-10-20 Valneva Austria Gmbh Polipéptido aislado de las proteínas de la toxina A y la toxina B de C. difficile y sus usos
LT2714910T (lt) * 2011-05-27 2018-03-12 Glaxosmithkline Biologicals Sa Imunogeninė kompozicija
PL3513806T3 (pl) * 2012-12-05 2023-05-15 Glaxosmithkline Biologicals Sa Imunogenna kompozycja

Also Published As

Publication number Publication date
TR201905272T4 (tr) 2019-05-21
PL3513806T3 (pl) 2023-05-15
PT2928489T (pt) 2019-05-28
CA2893435A1 (en) 2014-06-12
US9694064B2 (en) 2017-07-04
CN104884081A (zh) 2015-09-02
EP2928489A1 (en) 2015-10-14
CN112807422A (zh) 2021-05-18
LT3513806T (lt) 2023-04-11
WO2014086787A1 (en) 2014-06-12
US20170340719A1 (en) 2017-11-30
JP6290918B2 (ja) 2018-03-07
JP2016502551A (ja) 2016-01-28
SG11201503861UA (en) 2015-06-29
HUE043091T2 (hu) 2019-08-28
DK2928489T3 (en) 2019-04-23
US20150313984A1 (en) 2015-11-05
BR112015012841B1 (pt) 2022-05-03
ES2939307T3 (es) 2023-04-20
US10130694B2 (en) 2018-11-20
EP3513806A1 (en) 2019-07-24
AU2013354186A1 (en) 2014-06-12
AR093712A1 (es) 2015-06-17
SI3513806T1 (sl) 2023-04-28
JP6626521B2 (ja) 2019-12-25
EP3513806B1 (en) 2023-01-25
HRP20190711T1 (hr) 2019-05-31
ZA201503927B (en) 2017-11-29
LT2928489T (lt) 2019-04-10
PT3513806T (pt) 2023-03-02
HRP20230359T1 (hr) 2023-06-09
JP2018104446A (ja) 2018-07-05
DK3513806T3 (da) 2023-02-27
SI2928489T1 (sl) 2019-05-31
DK3513806T5 (da) 2024-09-02
HUE061273T2 (hu) 2023-06-28
CY1121560T1 (el) 2020-05-29
PL2928489T3 (pl) 2019-07-31
FI3513806T3 (fi) 2023-04-26
CA2893435C (en) 2024-11-12
EP2928489B1 (en) 2019-02-27
BR112015012841A2 (pt) 2017-09-26

Similar Documents

Publication Publication Date Title
ES2721930T3 (es) Composición inmunogénica
MX2015015239A (es) Composiciones y metodos.
EA201690280A1 (ru) Композиции и способы, относящиеся к выделенным эндофитам
MX2020010262A (es) Manufactura de neurotoxinas de clostridium botulinum recombinantes.
MX2014006630A (es) Vacuna a base toxina clostridium difficile.
BR112013000599A2 (pt) deuterado n-etil-n-fenil-1,2-di-hidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolino-3-carboxamida, os seus sais e suas utilizações
SI2909307T1 (sl) Kompozicije in metode, povezane z mutantnim toksinom clostridium difficile
BR112013000607A2 (pt) 5-cloro-4-hidroxi-1-metil-2-oxo-n-fenil-1,2-di-hidroquinolina-3-carboxamida, os sais e suas utilizações
AR101455A1 (es) Molécula portadora
BR112015021880A2 (pt) rearranjo de vírus influenza b
MX2015006915A (es) Preparacion de una bebida estable.
AR090668A1 (es) Anticuerpo anti-adamts-5, derivados y usos del mismo
TR201905787T4 (tr) Liyofilize TAT-NR2B9C formülasyonu.
MX2016008903A (es) Composicion adhesiva fusionada por calor en espuma para unir empaques de envases.
UA116697C2 (uk) Композиція для запобігання зараженню видами роду mycoplasma
UY35545A (es) Composiciones y procedimientos para inducir tolerancia inmunitaria a las proteínas factores de coag ulación
MX392514B (es) Vacuna para estreptococo del grupo a.
UY4238Q (es) Silla con respaldo en forma trapezoidal
CO7051011A2 (es) Anticuerpos recombinantes con especificidad dual por gangliósidos y su uso
AR088908A1 (es) Vacuna
EA201390670A1 (ru) Новый адъювант
GB201106162D0 (en) Combination vaccine
IN2014DN00168A (es)
CL2013000490S1 (es) Aspiradora
TWD186747S (zh) 破碎機